VEGF165	O
expressed	O
by	O
a	O
replication	O
-	O
deficient	O
recombinant	O
adenovirus	O
vector	O
induces	O
angiogenesis	O
in	O
vivo	O
.	O

To	O
evaluate	O
the	O
concept	O
that	O
localized	O
delivery	O
of	O
angiogenic	O
factors	O
via	O
virus	O
-	O
mediated	O
gene	O
transfer	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
ischemic	O
disorders	O
,	O
the	O
replication	O
-	O
deficient	O
adenovirus	O
(	O
Ad	O
)	O
vector	O
AdCMV	O
.	O
VEGF165	O
(	O
where	O
CMV	O
is	O
cytomegalovirus	O
and	O
VEGF	O
is	O
vascular	O
endothelial	O
growth	O
factor	O
)	O
containing	O
the	O
cDNA	O
for	O
human	O
VEGF165	O
,	O
a	O
secreted	O
endothelial	B-Cell
cell	I-Cell
-	O
specific	O
angiogenic	O
growth	O
factor	O
,	O
was	O
constructed	O
.	O

Human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	I-Cell
(	O
HUVECs	B-Cell
)	O
and	O
rat	B-Cell
aorta	I-Cell
smooth	I-Cell
muscle	I-Cell
cells	I-Cell
(	O
RASMCs	B-Cell
)	O
infected	O
with	O
AdCMV	O
.	O
VEGF165	O
(	O
5	O
and	O
20	O
plaque	O
-	O
forming	O
units	O
[	O
pfu	O
]	O
per	O
cell	B-Cell
)	O
demonstrated	O
VEGF	O
mRNA	O
expression	O
and	O
protein	O
secretion	O
into	O
the	O
supernatant	B-Organism_substance
.	O

Furthermore	O
,	O
the	O
conditioned	O
medium	O
from	O
these	O
cells	B-Cell
enhanced	O
vascular	B-Multi-tissue_structure
permeability	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
neither	O
VEGF	O
mRNA	O
nor	O
secreted	O
protein	O
was	O
found	O
in	O
uninfected	O
HUVECs	B-Cell
or	O
RASMCs	B-Cell
or	O
in	O
cells	B-Cell
infected	O
with	O
the	O
control	O
vector	O
AdCMV	O
.	O
beta	O
gal	O
(	O
where	O
beta	O
gal	O
is	O
beta	O
-	O
galactosidase	O
)	O
.	O

Assessment	O
of	O
starved	O
HUVECs	B-Cell
at	O
14	O
days	O
demonstrated	O
sixfold	O
more	O
cells	B-Cell
for	O
AdCMV	O
.	O
VEGF165	O
-	O
infected	O
HUVECs	B-Cell
(	O
20	O
pfu	O
per	O
cell	B-Cell
)	O
than	O
for	O
either	O
infected	O
or	O
uninfected	O
control	O
cells	B-Cell
.	O

RASMC	B-Cell
proliferation	O
was	O
unaffected	O
by	O
infection	O
with	O
AdCMV	O
.	O
VEGF165	O
.	O

When	O
plated	O
in	O
2	O
%	O
serum	B-Organism_substance
on	O
dishes	O
precoated	O
with	O
reconstituted	O
basement	B-Cellular_component
membrane	I-Cellular_component
(	O
Matrigel	O
)	O
,	O
HUVECs	B-Cell
infected	O
with	O
AdCMV	O
.	O
VEGF165	O
(	O
20	O
pfu	O
per	O
cell	B-Cell
)	O
differentiated	O
into	O
capillary	B-Tissue
-	I-Tissue
like	I-Tissue
structures	I-Tissue
.	O

Under	O
similar	O
conditions	O
,	O
both	O
uninfected	O
HUVECs	B-Cell
and	O
HUVECs	B-Cell
infected	O
with	O
AdCMV	O
.	O
beta	O
gal	O
did	O
not	O
differentiate	O
.	O

To	O
evaluate	O
the	O
ability	O
of	O
AdCMV	O
.	O
VEGF165	O
to	O
function	O
in	O
vivo	O
,	O
either	O
AdCMV	O
.	O

VEGF165	O
or	O
AdCMV	O
.	O
beta	O
gal	O
(	O
2	O
x	O
10	O
(	O
10	O
)	O
pfu	O
)	O
was	O
resuspended	O
in	O
0	O
.	O
5	O
mL	O
Matrigel	O
and	O
injected	O
subcutaneously	B-Immaterial_anatomical_entity
into	O
mice	O
.	O

Immunohistochemical	O
staining	O
demonstrated	O
VEGF	O
in	O
the	O
tissues	B-Tissue
surrounding	O
the	O
Matrigel	O
plugs	O
containing	O
AdCMV	O
.	O
VEGF165	O
up	O
to	O
3	O
weeks	O
after	O
injection	O
,	O
whereas	O
no	O
VEGF	O
was	O
found	O
in	O
the	O
control	O
plugs	O
with	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Two	O
weeks	O
after	O
injection	O
,	O
there	O
was	O
histological	O
evidence	O
of	O
neovascularization	O
in	O
the	O
tissues	B-Tissue
surrounding	O
the	O
Matrigel	O
containing	O
AdCMV	O
.	O
VEGF165	O
,	O
whereas	O
no	O
significant	O
angiogenesis	O
was	O
observed	O
in	O
response	O
to	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Furthermore	O
,	O
the	O
Matrigel	O
plugs	O
with	O
AdCMV	O
.	O
VEGF165	O
demonstrated	O
hemoglobin	O
content	O
fourfold	O
higher	O
than	O
the	O
plugs	O
with	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Together	O
,	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
are	O
consistent	O
with	O
the	O
concept	O
that	O
Ad	O
vectors	O
may	O
provide	O
a	O
useful	O
strategy	O
for	O
efficient	O
local	O
delivery	O
of	O
VEGF165	O
in	O
the	O
treatment	O
of	O
ischemic	O
diseases	O
.	O

